探索PPARγ激动剂在调节神经退行性疾病中的记忆障碍中的分子机制
Yousef Baghcheghi1,2, Fateme Razazpour2, Fatemeh Seyedi3
1Bio Environmental Health Hazards Research Center, Jiroft University of Medical Sciences, Jiroft, Iran.
Molecular biology reports
|August 31, 2024
概括
PPARγ激动剂通过改善记忆功能显示出治疗神经退行性疾病的前景. 这些化合物激活了增强记忆,保护大脑细胞和减少炎症的途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病会导致逐渐的记忆丧失和认知能力下降.
- 目前的治疗方法在阻止疾病进展方面有效性有限.
研究的目的:
- 审查氧酶增殖器激活受体玛 (PPARγ) 激动剂增强记忆力和减轻神经退行性疾病中的损伤的分子机制.
主要方法:
- 在神经退行性疾病模型中研究PPARγ激动剂的研究文献综述.
- 通过PPARγ激活调节的分子通路的分析.
主要成果:
- PPARγ激动剂增强突触可塑性,这对于记忆的形成和维护至关重要.
- 激活PPARγ促进神经保护并抑制神经炎症.
- PPARγ激动剂减轻氧化应激,调节粉样β代谢.
结论:
- PPARγ激动剂代表了改善神经退行性疾病中的记忆功能的潜在治疗策略.
- 准PPARγ可能提供一种新的方法来缓解认知衰退.
- 需要进一步的临床研究来验证PPARγ激动剂的疗效和安全性.
相关概念视频
Role of Neurotransmitters in Memory
485
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
485
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
110
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
110
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499


